ClinicalTrials.gg
TerminatedNCT06254495Updated Jul 6, 2026

A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

A Phase 1 interventional study of PF-08046044/SGN-35C in Hodgkin Disease, Lymphoma, T-Cell, Peripheral and Lymphoma, Large B-Cell, Diffuse, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Terminated at 33 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 1, Interventional, and Treatment

Why this study was terminated
The trial was terminated for strategic reasons due to portfolio reprioritization. The decision was not based on any safety or regulatory concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Hodgkin Disease by Pfizer — none open to participants now, none under way, none of them phase 3. Hodgkin Disease · Pfizer.

Enrollment
12th of 21
58 · median 70
Started
2024
with 1 other
Phase 1
11 of 22
none open now
Registered
21st of 22
by date

Among the 22 studies in Hodgkin Disease by Pfizer, this one is the 12th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2024, is one of 11 in phase 1, and was the 21st registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

None of the 22 studies in Hodgkin Disease by Pfizer is open now. The open studies under Hodgkin Disease, anywhere →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies in Hodgkin Disease by Pfizer as a file.
02

Study summary

This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL).

This clinical trial uses a drug called PF-08046044/SGN-35C . The study drug is in testing and has not been approved for sale. This is the first time SGN -35C will be used in people.

This study will test the safety of SGN-35C in participants with lymphoma. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease.

This study will have three parts. Parts A and B of the study will find out the best dose and dosing schedule for SGN-35C. Part C will use the dose found in parts A and B to find out how safe SGN-35C is and if it works to treat select lymphomas.

03

Conditions studied

  • Hodgkin Disease
  • Lymphoma, T-Cell, Peripheral
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Large-Cell, Anaplastic

Keywords

  • cHL
  • PTCL
  • sALCL
  • DLBCL
  • Seattle Genetics
  • ADC
  • Anti Drug Conjugate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Tumor type
  • For dose escalation and back fill and dose optimization (Parts A and B):

    • Participants with a confirmed lymphoid neoplasm who in the judgement of the investigator have no appropriate standard therapy available at the time of enrollment and are a candidate for PF-08046044/SGN- 35C treatment. Eligible subtypes and treatment status are as follows:

      • Participants with (R/R) cHL: should have received at least 3 prior systemic therapies including stem cell transplant [ASCT] (ASCT and the associated high-dose chemotherapy prior to ASCT are considered to be 1 prior line, along with post-transplant consolidation if progression has not occurred between transplant and start of consolidation) or an agent (or refused/were ineligible); or 2 prior systemic therapies if, according to the investigator, no other appropriate standard treatment is available.
      • Participants with R/R PTCL (excluding systematic anaplastic large cell lymphoma [sALCL]): should have received at least 2 prior systemic therapies, or 1 prior systemic therapy if, according to the investigator, no other appropriate standard treatment is available.
      • Participants with R/R sALCL: should have received at least 2 prior systemic therapies, including 1 brentuximab vedotin-containing regimen, or 1 including brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone.
      • Participants with R/R DLBCL: should have received at least 2 prior systemic therapies, including ASCT and chimeric antigen receptor (CAR) T-cell therapy, or were ineligible, or refused.
    • Participants with PTCL and DLBCL must have a detectable cluster of differentiation 30 (CD30) expression level (≥1%) in tumor tissue from the most recent obtained at or after relapse by local testing.
  • For dose expansion (Part C):

    • Participants are eligible irrespective of CD30 expression on tumor tissue; however, participants must provide tumor tissue for evaluation of CD30 expression from the most recent biopsy obtained at or after relapse.
    • Participants with cHL, PTCL, sALCL, and DLBCL: Eligible subtypes are the same as defined in Parts A and B
    • If activated, the biology cohort may enroll the populations included in Parts A, B, and C.
  • (ECOG) Performance Status score of ≤1
  • Fluorodeoxyglucose positron emission tomography (FDG-PET) avid and bidimensional as documented by radiographic technique (spiral computed tomography [CT] preferred)

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to any antibody-drug conjugates (ADCs) with camptothecin-based payload.
  • History of another within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of or death
  • Active central nervous system (CNS) disease related to the underlying malignancy. Participants with a history of CNS disease related to the underlying malignancy are allowed if prior CNS disease has been treated and the participant is clinically stable (defined as not currently receiving treatment for symptoms related to cerebral/meningeal disease and with no ongoing related AE).
  • Received previous infusion \<12 weeks prior to the first dose of SGN-35C.
  • Previous allogeneic stem cell transplant (SCT) if they meet any of the following criteria:

    • \<100 days from allogeneic SCT. Participants ≥100 days from allogeneic SCT who are stable without therapy for at least 12 weeks are permitted.
    • Active acute or chronic (GVHD) or receiving immunosuppressive therapy as treatment for or prophylaxis against GVHD.
  • History of GI bleeding, intestinal obstruction, or GI perforation within 6 months of initiation of trial treatment.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    PF-08046044/SGN-35C

    PF-08046044/SGN-35C Monotherapy

    Drug: PF-08046044/SGN-35C

Interventions

  • DrugPF-08046044/SGN-35C

    Given into the vein (IV; intravenously)

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention

    Time frame: Through 30-37 days after last study treatment, approximately 1 year

  2. Number of participants with laboratory abnormalities

    Time frame: Through 30-37 days after last study treatment, approximately 1 year

  3. Number of participants with dose modifications due to AEs

    Time frame: Up to approximately 1 year

  4. Number of participants with dose-limiting toxicities (DLTs)

    Time frame: Up to 21 days

  5. Number of participants with DLTs by dose level

    Time frame: Up to 21 days

Secondary outcomes

  1. Number of participants with antidrug antibodies (ADA)

    To be summarized using descriptive statistics

    Time frame: Through 30-37 days after last study treatment, approximately 1 year

  2. Area under the concentration time curve (AUC)

    To be summarized using descriptive statistics

    Time frame: Through 30-37 days after last study treatment, approximately 1 year

  3. Maximum concentration (Cmax)

    To be summarized using descriptive statistics

    Time frame: Through 30-37 days after last study treatment, approximately 1 year

  4. Time at which the maximum concentration occurs (Tmax)

    To be summarized using descriptive statistics

    Time frame: Through 30-37 days after last study treatment, approximately 1 year

  5. Apparent terminal half-life (t1/2)

    To be summarized using descriptive statistics

    Time frame: Through 30-37 days after last study treatment, approximately 1 year

  6. Trough concentration (Ctrough)

    To be summarized using descriptive statistics

    Time frame: Through 30-37 days after last study treatment, approximately 1 year

  7. Objective response rate (ORR) as assessed by the investigator

    A participant is determined to have an objective response if, based on Lugano criteria (Cheson 2014), they achieve a complete response (CR) or partial response (PR) as assessed by the investigator. The ORR is defined as the percentage of participants with an objective response.

    Time frame: Up to approximately 1 year

  8. CR rate as assessed by the investigator

    CR rate is defined as the proportion of participants with CR.

    Time frame: Up to approximately 1 year

  9. Duration of response (DOR)

    DOR is defined as the time from the start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per Lugano criteria (Cheson 2014) as assessed by the investigator or to death due to any cause, whichever comes first.

    Time frame: Up to approximately 1 year

07

Study locations

33 sites
  • City of Hope (City of Hope National Medical Center, City Of Hope Medical Center)
    Duarte, California 91010, United States
  • IP Address: City of Hope Investigational Drug Services(IDS)
    Duarte, California 91010, United States
  • University of California, San Francisco Medical Center
    San Francisco, California 94143, United States
  • Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center
    Coral Gables, Florida 33146, United States
  • University of Miami Hospital and Clinics - Deerfield Beach
    Deerfield Beach, Florida 33442, United States
  • Sylvester Comprehensive Cancer Center - Hollywood
    Hollywood, Florida 33021, United States
  • Griffin Cancer Research Building (GCRB)
    Miami, Florida 33136, United States
  • University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • University Of Miami Hospitals And Clinics
    Miami, Florida 33136, United States
  • Sylvester Comprehensive Cancer Center - Kendall
    Miami, Florida 33176, United States
  • The University of Kansas Cancer Center, Investigational Drug Services
    Fairway, Kansas 66205, United States
  • University of Kansas Clinical Research Center
    Fairway, Kansas 66205, United States
  • The University of Kansas Hospital Cambridge North Tower A
    Kansas City, Kansas 66160, United States
  • The University of Kansas Hospital
    Kansas City, Kansas 66160, United States
  • The University of Kansas Medical Center Medical Office Building
    Kansas City, Kansas 66160, United States
  • The University of Kansas Cancer Center - Overland Park
    Overland Park, Kansas 66210, United States
  • The University of Kansas Cancer Center - Indian Creek Campus
    Overland Park, Kansas 66211, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • The University of Kansas Cancer Center - Lee's Summit
    Lee's Summit, Missouri 64064, United States
  • Nebraska Medicine - Bellevue Medical Center
    Bellevue, Nebraska 68123, United States
  • Nebraska Medical Center
    Omaha, Nebraska 68105, United States
  • Nebraska Medicine - Village Pointe
    Omaha, Nebraska 68118, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Robert Wood Johnson University Hospital
    New Brunswick, New Jersey 08901, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • Fred Hutchinson Cancer Research Center | Seattle, WA
    Seattle, Washington 98109, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • Rigshospitalet University Hospital of Copenhagen
    Copenhagen Ø, DK 2100, Denmark
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Centro Ricerche Cliniche di Verona s.r.l.
    Verona, 37134, Italy
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • The Royal Marsden NHS Foundation Trust (RM)
    Sutton, Surrey SM2 5PT, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Apr 2026, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2024
First posted
Feb 12, 2024
StartActual
May 28, 2024
Primary completionActual
Apr 13, 2026
CompletionActual
Apr 13, 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06254495
Responsible party
Sponsor
First posted
Feb 12, 2024
Start date
May 28, 2024
Primary completion
Apr 13, 2026
Completion
Apr 13, 2026
Last update
Jul 6, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion